alosetron has been researched along with Dementia Praecox in 1 studies
alosetron : A pyrido[4,3-b]indole compound having a 5-methyl-1H-imidazol-4-ylmethyl group at the 2-position.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Alosetron is under clinical development for the treatment of schizophrenia." | 5.08 | Effect of alosetron (a new 5-HT3 receptor antagonist) on the pharmacokinetics of haloperidol in schizophrenic patients. ( Gupta, SK; Kunka, RL; Lloyd, T; Metz, A; Perel, JM; Rudolph, G, 1995) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (100.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Gupta, SK | 1 |
| Kunka, RL | 1 |
| Metz, A | 1 |
| Lloyd, T | 1 |
| Rudolph, G | 1 |
| Perel, JM | 1 |
1 trial available for alosetron and Dementia Praecox
| Article | Year |
|---|---|
Effect of alosetron (a new 5-HT3 receptor antagonist) on the pharmacokinetics of haloperidol in schizophrenic patients.
Topics: Adult; Carbolines; Double-Blind Method; Female; Haloperidol; Humans; Male; Middle Aged; Schizophreni | 1995 |